Cargando…

ELF5 isoform expression is tissue-specific and significantly altered in cancer

BACKGROUND: E74-like factor 5 (ELF5) is an epithelial-specific member of the E26 transforming sequence (ETS) transcription factor family and a critical regulator of cell fate in the placenta, pulmonary bronchi, and milk-producing alveoli of the mammary gland. ELF5 also plays key roles in malignancy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Piggin, Catherine L., Roden, Daniel L., Gallego-Ortega, David, Lee, Heather J., Oakes, Samantha R., Ormandy, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704400/
https://www.ncbi.nlm.nih.gov/pubmed/26738740
http://dx.doi.org/10.1186/s13058-015-0666-0
_version_ 1782408858196508672
author Piggin, Catherine L.
Roden, Daniel L.
Gallego-Ortega, David
Lee, Heather J.
Oakes, Samantha R.
Ormandy, Christopher J.
author_facet Piggin, Catherine L.
Roden, Daniel L.
Gallego-Ortega, David
Lee, Heather J.
Oakes, Samantha R.
Ormandy, Christopher J.
author_sort Piggin, Catherine L.
collection PubMed
description BACKGROUND: E74-like factor 5 (ELF5) is an epithelial-specific member of the E26 transforming sequence (ETS) transcription factor family and a critical regulator of cell fate in the placenta, pulmonary bronchi, and milk-producing alveoli of the mammary gland. ELF5 also plays key roles in malignancy, particularly in basal-like and endocrine-resistant forms of breast cancer. Almost all genes undergo alternative transcription or splicing, which increases the diversity of protein structure and function. Although ELF5 has multiple isoforms, this has not been considered in previous studies of ELF5 function. METHODS: RNA-sequencing data for 6757 samples from The Cancer Genome Atlas were analyzed to characterize ELF5 isoform expression in multiple normal tissues and cancers. Extensive in vitro analysis of ELF5 isoforms, including a 116-gene quantitative polymerase chain reaction panel, was performed in breast cancer cell lines. RESULTS: ELF5 isoform expression was found to be tissue-specific due to alternative promoter use but altered in multiple cancer types. The normal breast expressed one main isoform, while in breast cancer there were subtype-specific alterations in expression. Expression of other ETS factors was also significantly altered in breast cancer, with the basal-like subtype demonstrating a distinct ETS expression profile. In vitro inducible expression of the full-length isoforms 1 and 2, as well as isoform 3 (lacking the Pointed domain) had similar phenotypic and transcriptional effects. CONCLUSIONS: Alternative promoter use, conferring differential regulatory responses, is the main mechanism governing ELF5 action rather than differential transcriptional activity of the isoforms. This understanding of expression and function at the isoform level is a vital first step in realizing the potential of transcription factors such as ELF5 as prognostic markers or therapeutic targets in cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0666-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4704400
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47044002016-01-08 ELF5 isoform expression is tissue-specific and significantly altered in cancer Piggin, Catherine L. Roden, Daniel L. Gallego-Ortega, David Lee, Heather J. Oakes, Samantha R. Ormandy, Christopher J. Breast Cancer Res Research Article BACKGROUND: E74-like factor 5 (ELF5) is an epithelial-specific member of the E26 transforming sequence (ETS) transcription factor family and a critical regulator of cell fate in the placenta, pulmonary bronchi, and milk-producing alveoli of the mammary gland. ELF5 also plays key roles in malignancy, particularly in basal-like and endocrine-resistant forms of breast cancer. Almost all genes undergo alternative transcription or splicing, which increases the diversity of protein structure and function. Although ELF5 has multiple isoforms, this has not been considered in previous studies of ELF5 function. METHODS: RNA-sequencing data for 6757 samples from The Cancer Genome Atlas were analyzed to characterize ELF5 isoform expression in multiple normal tissues and cancers. Extensive in vitro analysis of ELF5 isoforms, including a 116-gene quantitative polymerase chain reaction panel, was performed in breast cancer cell lines. RESULTS: ELF5 isoform expression was found to be tissue-specific due to alternative promoter use but altered in multiple cancer types. The normal breast expressed one main isoform, while in breast cancer there were subtype-specific alterations in expression. Expression of other ETS factors was also significantly altered in breast cancer, with the basal-like subtype demonstrating a distinct ETS expression profile. In vitro inducible expression of the full-length isoforms 1 and 2, as well as isoform 3 (lacking the Pointed domain) had similar phenotypic and transcriptional effects. CONCLUSIONS: Alternative promoter use, conferring differential regulatory responses, is the main mechanism governing ELF5 action rather than differential transcriptional activity of the isoforms. This understanding of expression and function at the isoform level is a vital first step in realizing the potential of transcription factors such as ELF5 as prognostic markers or therapeutic targets in cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0666-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-07 2016 /pmc/articles/PMC4704400/ /pubmed/26738740 http://dx.doi.org/10.1186/s13058-015-0666-0 Text en © Piggin et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Piggin, Catherine L.
Roden, Daniel L.
Gallego-Ortega, David
Lee, Heather J.
Oakes, Samantha R.
Ormandy, Christopher J.
ELF5 isoform expression is tissue-specific and significantly altered in cancer
title ELF5 isoform expression is tissue-specific and significantly altered in cancer
title_full ELF5 isoform expression is tissue-specific and significantly altered in cancer
title_fullStr ELF5 isoform expression is tissue-specific and significantly altered in cancer
title_full_unstemmed ELF5 isoform expression is tissue-specific and significantly altered in cancer
title_short ELF5 isoform expression is tissue-specific and significantly altered in cancer
title_sort elf5 isoform expression is tissue-specific and significantly altered in cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704400/
https://www.ncbi.nlm.nih.gov/pubmed/26738740
http://dx.doi.org/10.1186/s13058-015-0666-0
work_keys_str_mv AT piggincatherinel elf5isoformexpressionistissuespecificandsignificantlyalteredincancer
AT rodendaniell elf5isoformexpressionistissuespecificandsignificantlyalteredincancer
AT gallegoortegadavid elf5isoformexpressionistissuespecificandsignificantlyalteredincancer
AT leeheatherj elf5isoformexpressionistissuespecificandsignificantlyalteredincancer
AT oakessamanthar elf5isoformexpressionistissuespecificandsignificantlyalteredincancer
AT ormandychristopherj elf5isoformexpressionistissuespecificandsignificantlyalteredincancer